ONO-8711 | 308325-38-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ONO-8711
• 英文别名: 6-[(2S,3S)-3-(4-chloro-2-methylphenylsulfonylaminomethyl)bicyclo[2.2.2]octan-2-yl]-5Z-hexenoic acid；(Z)-6-[(2S,3S)-3-[[(4-chloro-2-methylphenyl)sulfonylamino]methyl]-2-bicyclo[2.2.2]octanyl]hex-5-enoic acid
• CAS: 308325-38-4
• 化学式: C₂₂H₃₀ClNO₄S
• 分子量: 440.003
• InChiKey: VVEXPDRCGCQELD-NHIVGFGBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Remedies for depression containing ep1 antagonist as the active ingredient
  申请人：——

  公开号：US20040082653A1

  公开（公告）日：2004-04-29

  A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP 1 receptor which a prostaglandin E 2 receptor subtype. EP 1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

  一种用于治疗和/或预防抑郁症的药物组合物，包括一种具有EP1受体拮抗活性的化合物，该受体是前列腺素E2受体亚型。EP1拮抗剂对于治疗抑郁症很有用，例如内源性抑郁症，反应性抑郁症，耐受性抑郁症，神经学抑郁状态，脑器质性心境障碍的抑郁状态。
• REMEDIES FOR URINARY FREQUENCY
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1447096A1

  公开（公告）日：2004-08-18

  The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP1 receptor which is a prostaglandin E2 receptor subtype. A compound having an antagonism to an EP1 receptor antagonistically acts on an EP1 receptor which is a prostaglandin PGE2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).

  本发明涉及一种用于治疗和/或预防花粉尿症的制剂，该制剂包含一种对前列腺素E2受体亚型的EP1受体具有拮抗作用的化合物。具有 EP1 受体拮抗作用的化合物可拮抗属于前列腺素 PGE2 受体亚型的 EP1 受体，并在诱导花粉尿症的模型中显著显示出抑制排尿次数的活性。因此，它对治疗和/或预防花粉尿症（由神经性膀胱、神经性膀胱、刺激性膀胱、不稳定膀胱、良性前列腺肥大等引起的花粉尿症）有效。
• REMEDY FOR URINARY TRACT DISEASES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1642594A1

  公开（公告）日：2006-04-05

  A preventive and/or a remedy for urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence which comprises a combination of compound having antagonism to EP1 with another compound having antagonism to EP3 each selected from among prostaglandin E2 receptors. The combination of an EP1 antagonist with an EP3 antagonist is useful in preventing and/or treating urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence, because of showing effect of improving urine retaining ability, improving bladder compliance, relieving hypertonic detrusor muscle and normalizing bladder perception.

  一种具有尿急、膀胱痛、尿频或尿失禁等症状的尿路疾病的预防和/或治疗方法，它包括具有EP1拮抗作用的化合物与另一种具有EP3拮抗作用的化合物的组合，每种化合物都选自前列腺素E2受体。EP1拮抗剂与EP3拮抗剂的组合有助于预防和/或治疗伴有尿急、膀胱痛、尿频或尿失禁等症状的尿路疾病，因为其显示出改善尿液保留能力、改善膀胱顺应性、缓解高张力的逼尿肌和使膀胱感知正常化的效果。
• Remedies for urinary frequency
  申请人：Maruyama Takayuki

  公开号：US20060100195A1

  公开（公告）日：2006-05-11

  The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP 1 receptor which is a prostaglandin E 2 receptor subtype. A compound having an antagonism to an EP 1 receptor antagonistically acts on an EP 1 receptor which is a prostaglandin PGE 2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).

  本发明涉及一种用于治疗和/或预防花粉尿症的制剂，该制剂包含一种具有拮抗 EP 1 受体（前列腺素 E 2 受体亚型的拮抗剂。具有拮抗 EP 1 受体具有拮抗作用的化合物可拮抗 EP 1 受体上起拮抗作用，该受体是前列腺素 PGE 2 受体亚型的 EP 1 受体上，并在诱导花粉尿的模型中明显显示出抑制排尿次数的活性。因此，它对治疗和/或预防花粉尿（由神经性膀胱、神经性膀胱、刺激性膀胱、不稳定膀胱、良性前列腺肥大等引起的花粉尿）有效。
• METHOD OF TREATMENT
  申请人：AstraZeneca AB

  公开号：EP1370266A1

  公开（公告）日：2003-12-17